Companies / Netherlands
Netherlands Approves Roche's High-Dose HCV Drug
April 2006 | Product LaunchRoche's high-dose formulation of Copegus (ribavirin) has been approved for the treatment of hepatitis C virus (HCV) infection in the Netherlands. Subsequent approvals in Europe via the mutual recognition procedure are expected in the next three months. However, the product will not be submitted for registration in the US.
Sorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Western Europe Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Western Europe Pharma & Healthcare Insight please click on the trial link below.
